Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Amyloidosis and IMS 2024

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Current and emerging immune therapies in AL amyloidosis: updates on HBI0101 & bispecifics 2:25
Current and emerging immune therapies in AL amyloidosis: updates on HBI0101 & bispecifics
Eyal Lebel • 30 Sep 2024
Key challenges that remain in the diagnosis of AL amyloidosis 1:49
Key challenges that remain in the diagnosis of AL amyloidosis
Eyal Lebel • 30 Sep 2024
Early detection of amyloidosis, MGUS, and smoldering myeloma: single-center real-world experience 1:34
Early detection of amyloidosis, MGUS, and smoldering myeloma: single-center real-world experience
Natalia Schütz • 27 Sep 2024
The value of early diagnosis in amyloidosis and the impact of a delayed diagnosis for patients 1:15
The value of early diagnosis in amyloidosis and the impact of a delayed diagnosis for patients
Pedro Vianna • 26 Sep 2024
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics 1:14
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
Pedro Vianna • 26 Sep 2024
Impact of the addition of daratumumab to the frontline treatment of patients with AL amyloidosis 2:43
Impact of the addition of daratumumab to the frontline treatment of patients with AL amyloidosis
Elena Alejo • 26 Sep 2024
The safety and efficacy of elranatamab in patients with R/R AL amyloidosis 0:55
The safety and efficacy of elranatamab in patients with R/R AL amyloidosis
Pedro Vianna • 26 Sep 2024
The key unmet needs in the frontline and R/R setting in amyloidosis 1:12
The key unmet needs in the frontline and R/R setting in amyloidosis
Pedro Vianna • 26 Sep 2024

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Amyloidosis Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals